Develops drugs for cancer, arthritis, and infectious diseases.
Sep 2026Revenue $99.3B/yrExpenses $81.6B/yr
No trend
Figures by year
Is Johnson & Johnson profitable?
Yes. In the 12 months to Sep 2026, revenue was $99.3B and expenses $81.6B.
| Fiscal year to | Revenue | Expenses | Pre-tax profit |
|---|---|---|---|
| Dec 2025 | $94.2B | $61.6B | $32.6B |
| Dec 2024 | $88.8B | $72.1B | $16.7B |
| Dec 2023 | $85.2B | $70.1B | $15.1B |
| Jan 2023 | $80.0B | $60.6B | $19.4B |
| Jan 2022 | $78.7B | $59.6B | $19.2B |
| Jan 2021 | $82.6B | $66.1B | $16.5B |
| Dec 2019 | $82.1B | $64.7B | $17.3B |
| Dec 2018 | $81.6B | $63.6B | $18.0B |
| Dec 2017 | $76.5B | $58.8B | $17.7B |
| Jan 2017 | $71.9B | $52.1B | $19.8B |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.